SAHPRA’s website has revamped navigation for easier access to key documentation & E-Services
Pretoria, 11 March 2024 – The Communications and Public Relations Unit has again re-evaluated the na...
11 March, 24Pretoria, 11 March 2024 – The Communications and Public Relations Unit has again re-evaluated the na...
11 March, 24Pretoria, 11 March 2024 – On 05 January 2023, the COVID Care Alliance NPC and other applicants broug...
11 March, 24Pretoria, 19 February 2024 – The Department of Health has noted a misleading voice-note making round...
19 February, 24AUDA-NEPAD has published its 2023 Highlights Edition on African Medicines Regulatory Harmonization (...
15 February, 24There have been several cases around the world in which Tranexamic acid has been administered intrat...
21 December, 23The South African Health Products Regulatory Authority (SAHPRA) would like to inform you of a signal...
19 October, 21In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Product...
10 November, 20SAHPRA alerts all healthcare professionals about the risk of serious heart problems, seizures, coma ...
01 November, 20The recall was initiated because of numerous complaints received by SAHPRA due to a countrywide outbreak across the country regarding patients who developed a rare fungal pathogen, Wickerhamomyces anomalus (previously Candida pelliculosa), following the use of Lubri-A use. Following a collaborative outbreak investigation, the source was found to have contaminated several batches of the product, Lubri-A-Sterile Lubricating 2.5 g Jelly sachets.
The recall was initiated because some of the containers possess defective primary packaging, resulting in the loosening of the seal on certain packages. The company confirmed that this faulty seal, combined with the hygroscopic nature of the product, causes the product to become moist.
This recall was initiated due to discolouration of tablets.